BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Authors » Nuala Moran

Articles by Nuala Moran

OGS Gains European Approval, Partner For Gaucher's Product

July 29, 2002
By Nuala Moran
LONDON - Oxford GlycoSciences plc said Friday it received approval in Europe for Vevesca, an oral treatment for Gaucher's disease that was turned down by the FDA on June 24. (BioWorld Today)
Read More

Anglo-Japanese Firm Formed Around Liposome Gene Vectors

July 24, 2002
By Nuala Moran
LONDON - The first Anglo-Japanese biotechnology company, IC-Vec Ltd., has been spun out from Imperial College London with £3.1 million (US$4.8 million) of Japanese venture capital and intellectual property from Mitsubishi Chemical Corp., Japan's largest chemical company. (BioWorld International)
Read More

Genetix Group, MRC Enter £2.5M Project On Protein Interactions

July 24, 2002
By Nuala Moran

Anglo-Japanese Firm Formed Around Liposome Gene Vectors

July 24, 2002
By Nuala Moran
LONDON - The first Anglo-Japanese biotechnology company, IC-Vec Ltd., has been spun out from Imperial College London with £3.1 million (US$4.8 million) of Japanese venture capital and intellectual property from Mitsubishi Chemical Corp., Japan's largest chemical company. (BioWorld International)
Read More

Genetix Group, MRC Enter £2.5M Project On Protein Interactions

July 24, 2002
By Nuala Moran

Inpharmatica Signs Daiichi To 3-Year BioPendium Deal

July 17, 2002
By Nuala Moran

Ardana Buys Europeptides For EUR28M, Expands Portfolio

July 17, 2002
By Nuala Moran
LONDON - Ardana Bioscience Ltd. acquired Europeptides GEIE for €28 million (US$28.3 million), along with intellectual property from Europeptides' owner, Zentaris AG, in a deal that Ardana says puts it one to two years closer to a marketed product. (BioWorld International)
Read More

IsoTis Establishes Chienna To Focus On Protein Delivery

July 17, 2002
By Nuala Moran

Inpharmatica Signs Daiichi To 3-Year BioPendium Deal

July 17, 2002
By Nuala Moran

IsoTis Establishes Chienna To Focus On Protein Delivery

July 17, 2002
By Nuala Moran
Previous 1 2 … 495 496 497 498 499 500 501 502 503 … 527 528 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing